1 Min Read
April 18 (Reuters) - Cellnovo Group SA:
* Cellnovo acquires commercial license for artificial pancreas technology from Typezero Technologies
* Integration and commercialization of Typezero's artificial pancreas (ap) technology into Cellnovo's mobile diabetes management systems.
* Integration efforts are currently underway with a product launch expected in 2018; no financial terms have been disclosed Source text for Eikon: Further company coverage: (Gdynia Newsroom:)